Two Sigma Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,089,112
| Closed | -$31.9M | – | 253 |
|
|
2025
Q4 | $31.9M | Sell |
4,089,112
-151,600
| -4% | -$1.1M | 0.06% | 247 |
|
|
2025
Q3 | $32.2M | Buy |
4,240,712
+12,300
| +0.3% | +$102K | 0.06% | 241 |
|
|
2025
Q2 | $37.9M | Buy |
4,228,412
+1,007,700
| +31% | +$9.38M | 0.08% | 225 |
|
|
2025
Q1 | $24.2M | Buy |
3,220,712
+720,900
| +29% | +$5.81M | 0.05% | 295 |
|
|
2024
Q4 | $18.8M | Buy |
2,499,812
+318,800
| +15% | +$2.42M | 0.04% | 333 |
|
|
2024
Q3 | $16.6M | Buy |
2,181,012
+261,500
| +14% | +$1.99M | 0.04% | 359 |
|
|
2024
Q2 | $11.9M | Sell |
1,919,512
-553,900
| -22% | -$3.06M | 0.03% | 490 |
|
|
2024
Q1 | $12.6M | Buy |
2,473,412
+205,400
| +9% | +$1.16M | 0.03% | 457 |
|
|
2023
Q4 | $13.6M | Sell |
2,268,012
-100,900
| -4% | -$585K | 0.03% | 427 |
|
|
2023
Q3 | $16.8M | Buy |
2,368,912
+231,300
| +11% | +$1.66M | 0.04% | 348 |
|
|
2023
Q2 | $15M | Sell |
2,137,612
-65,100
| -3% | -$522K | 0.04% | 374 |
|
|
2023
Q1 | $18.4M | Buy |
2,202,712
+231,800
| +12% | +$2.23M | 0.05% | 355 |
|
|
2022
Q4 | $22.6M | Sell |
1,970,912
-44,900
| -2% | -$560K | 0.06% | 304 |
|
|
2022
Q3 | $25.4M | Sell |
2,015,812
-67,600
| -3% | -$870K | 0.07% | 266 |
|
|
2022
Q2 | $22M | Buy |
2,083,412
+312,400
| +18% | +$3.22M | 0.06% | 305 |
|
|
2022
Q1 | $28.8M | Sell |
1,771,012
-380,900
| -18% | -$6.11M | 0.08% | 243 |
|
|
2021
Q4 | $29.8M | Buy |
2,151,912
+230,900
| +12% | +$3.06M | 0.07% | 229 |
|
|
2021
Q3 | $27.6M | Buy |
1,921,012
+1,212,900
| +171% | +$19.1M | 0.07% | 251 |
|
|
2021
Q2 | $11.2M | Buy |
708,112
+483,900
| +216% | +$6.57M | 0.03% | 523 |
|
|
2021
Q1 | $2.28M | Sell |
224,212
-1,085,500
| -83% | -$11.2M | 0.01% | 1204 |
|
|
2020
Q4 | $9.76M | Sell |
1,309,712
-579,600
| -31% | -$2.99M | 0.03% | 577 |
|
|
2020
Q3 | $6.49M | Sell |
1,889,312
-229,500
| -11% | -$984K | 0.02% | 678 |
|
|
2020
Q2 | $10.1M | Buy |
2,118,812
+518,900
| +32% | +$2.07M | 0.03% | 547 |
|
|
2020
Q1 | $3.2M | Buy |
1,599,912
+98,100
| +7% | +$270K | 0.01% | 881 |
|
|
2019
Q4 | $5.18M | Buy |
1,501,812
+626,900
| +72% | +$1.58M | 0.01% | 835 |
|
|
2019
Q3 | $2.51M | Buy |
874,912
+435,300
| +99% | +$1.35M | 0.01% | 1016 |
|
|
2019
Q2 | $1.67M | Buy |
439,612
+245,800
| +127% | +$1.48M | ﹤0.01% | 1292 |
|
|
2019
Q1 | $1.58M | Buy |
193,812
+28,400
| +17% | +$243K | ﹤0.01% | 1320 |
|
|
2018
Q4 | $1.33M | Sell |
165,412
-32,800
| -17% | -$255K | ﹤0.01% | 1355 |
|
|
2018
Q3 | $1.51M | Buy |
198,212
+29,000
| +17% | +$195K | ﹤0.01% | 1350 |
|
|
2018
Q2 | $970K | Buy |
169,212
+75,412
| +80% | +$415K | ﹤0.01% | 1617 |
|
|
2018
Q1 | $447K | Sell |
93,800
-600
| -0.6% | -$3.08K | ﹤0.01% | 1855 |
|
|
2017
Q4 | $464K | Buy |
94,400
+8,900
| +10% | +$43.1K | ﹤0.01% | 1789 |
|
|
2017
Q3 | $448K | Buy |
85,500
+21,988
| +35% | +$113K | ﹤0.01% | 1786 |
|
|
2017
Q2 | $353K | Buy |
63,512
+33,100
| +109% | +$202K | ﹤0.01% | 1912 |
|
|
2017
Q1 | $255K | Buy |
+30,412
| New | +$212K | ﹤0.01% | 2137 |
|
|
2015
Q1 | – | Sell |
-14,612
| Closed | -$178K | – | 1914 |
|
|
2014
Q4 | $178K | Sell |
14,612
-8,300
| -36% | -$91.7K | ﹤0.01% | 2241 |
|
|
2014
Q3 | $224K | Sell |
22,912
-36,700
| -62% | -$450K | ﹤0.01% | 2075 |
|
|
2014
Q2 | $760K | Buy |
+59,612
| New | +$580K | 0.01% | 1358 |
|
Other funds holding BCRX
RCM
DM
VPM
VCM
TCM
PA
VPC